Arvinas Inc., of New Haven, Conn., reported preclinical data on its tau-targeted Protac protein degrader program at the Alzheimer's Association International Conference in Los Angeles. After parenteral administration of the drug, more than 95% of pathologic tau protein was eliminated in the brain of a mouse tauopathy model.

Obseva SA, of Geneva, said its board approved an increase of its share capital from 45.5 million shares to 48.6 million. The shares will be listed on the SIX Swiss Exchange on or around July 23.

Xenetic Biosciences Inc., of Framingham, Mass., priced a public offering of 2.3 million shares and warrants to purchase up to 2.3 million shares.

Cytori Therapeutics Inc., of Austin, Texas, is changing its name to Plus Therapeutics Inc. to reflect its new focus on developing innovative drugs. It has reserved a new stock symbol, PSTV, and plans to submit notice of the company name change to Nasdaq.

Seattle Genetics Inc., of Bothell, Wash., reported U.S. and Canadian sales of Adcetris (brentuximab vedotin), its antibody-drug conjugate targeting CD30 for lymphoma, totaling $159 million for the second quarter, marking a 30% increase over net sales in the second quarter of 2018 and topping consensus estimates by roughly 7%. 

Adverum Biotechnologies Inc., of Menlo Park, Calif., appointed Carol Hoang vice president, medical affairs and James Shahbazian vice president, finance.